Axogen CEO awarded 98,000 RSUs

DALE MICHAEL D reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

DALE MICHAEL D reported acquisition or exercise transactions in this Form 4 filing.

Axogen, Inc. reported that Chief Executive Officer Michael D Dale received a grant of 98,000 restricted stock units (RSUs) on February 26, 2026. Each RSU represents a contingent right to receive one share of Axogen common stock. The RSUs vest over four years: 50% of the shares vest on February 26, 2028, with an additional 25% vesting on February 26, 2029 and the final 25% on February 26, 2030. Vested shares will be delivered to the CEO on each vesting date, aligning his compensation more closely with the company’s long-term stock performance.

Insider Trade Summary

Grant/Award: 98,000 shares

Grant/Award 1 txn

Insider DALE MICHAEL D

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	98,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 98,000 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
2. F2. All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Axogen (AXGN) report in this Form 4?

Axogen reported that CEO Michael D Dale received a grant of 98,000 restricted stock units. These equity awards tie part of his compensation to future Axogen share performance over a multi-year vesting schedule.

How many restricted stock units did the Axogen (AXGN) CEO receive?

The Axogen CEO received 98,000 restricted stock units. Each unit represents a contingent right to one share of Axogen common stock, subject to the vesting schedule described in the Form 4 footnotes.

When do the Axogen (AXGN) CEO’s 98,000 RSUs vest?

The RSUs fully vest on February 26, 2030. Half of the 98,000 units vest on February 26, 2028, and 25% vest on each of the next two anniversaries, in 2029 and 2030.

What does each Axogen (AXGN) restricted stock unit represent?

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. Shares are actually delivered only when the units vest according to the specified schedule.

Did the Axogen (AXGN) CEO buy shares for cash in this Form 4 transaction?

No, this Form 4 shows an equity award, not a cash purchase. The CEO received 98,000 restricted stock units as a grant, with a reported price per unit of $0.0000 in the filing.

When will the Axogen (AXGN) CEO receive the shares underlying these RSUs?

The CEO will receive the underlying Axogen shares on each vesting date. Vested shares corresponding to each tranche are delivered when the units vest in 2028, 2029, and 2030.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/27/2026 - 04:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DALE MICHAEL D

(Last) (First) (Middle)

13631 PROGRESS BLVD.,

SUITE 400

(Street)

ALACHUA FL 32615

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/26/2026	02/26/2026	A		98,000		(2)	(2)	Common Stock	98,000	$0	98,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

2. All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

Remarks:

	/s/ Mark Began, as attorney-in-fact for Michael Dale	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.